TScan Therapeutics (NASDAQ:TCRX) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a report issued on Friday morning,Benzinga reports. The firm currently has a $15.00 price objective on the stock.

A number of other research firms have also weighed in on TCRX. Needham & Company LLC restated a “buy” rating and issued a $11.00 target price on shares of TScan Therapeutics in a report on Tuesday, November 12th. Wedbush reiterated an “outperform” rating and issued a $10.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, November 5th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $12.00.

TScan Therapeutics Stock Performance

Shares of TCRX stock opened at $4.20 on Friday. The company has a current ratio of 9.56, a quick ratio of 7.77 and a debt-to-equity ratio of 0.13. The firm has a fifty day simple moving average of $5.27 and a two-hundred day simple moving average of $6.43. TScan Therapeutics has a 12 month low of $3.73 and a 12 month high of $9.69. The firm has a market capitalization of $222.47 million, a PE ratio of -3.96 and a beta of 0.79.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.03. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The company had revenue of $1.05 million during the quarter, compared to the consensus estimate of $2.86 million. Analysts forecast that TScan Therapeutics will post -1.14 EPS for the current fiscal year.

Insiders Place Their Bets

In other TScan Therapeutics news, Director Barbara Klencke bought 5,000 shares of the business’s stock in a transaction on Monday, September 23rd. The stock was purchased at an average price of $5.29 per share, for a total transaction of $26,450.00. Following the completion of the transaction, the director now directly owns 45,000 shares of the company’s stock, valued at $238,050. This trade represents a 12.50 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Zoran Zdraveski sold 164,686 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $5.78, for a total transaction of $951,885.08. Following the completion of the sale, the insider now directly owns 4,716 shares in the company, valued at approximately $27,258.48. This trade represents a 97.22 % decrease in their position. The disclosure for this sale can be found here. Insiders bought 15,000 shares of company stock valued at $82,550 over the last ninety days. 2.76% of the stock is currently owned by insiders.

Institutional Investors Weigh In On TScan Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC grew its position in shares of TScan Therapeutics by 8.1% in the third quarter. Geode Capital Management LLC now owns 973,466 shares of the company’s stock valued at $4,849,000 after purchasing an additional 72,967 shares in the last quarter. Barclays PLC boosted its stake in TScan Therapeutics by 341.1% in the 3rd quarter. Barclays PLC now owns 58,067 shares of the company’s stock worth $289,000 after purchasing an additional 44,903 shares during the period. XTX Topco Ltd bought a new position in TScan Therapeutics in the 3rd quarter worth about $112,000. Wellington Management Group LLP grew its holdings in TScan Therapeutics by 38.9% during the 3rd quarter. Wellington Management Group LLP now owns 126,345 shares of the company’s stock valued at $629,000 after buying an additional 35,404 shares in the last quarter. Finally, State Street Corp increased its position in shares of TScan Therapeutics by 24.4% during the third quarter. State Street Corp now owns 756,499 shares of the company’s stock valued at $3,767,000 after buying an additional 148,414 shares during the period. Institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.